Engineers India FPO – A Value BUY

  • Date – 29th Jan 2016; Issue Period: today, one day only
  • CMP: Rs 194; FPO Floor Pricing: Rs 189/share. Retail gets a 5% discount
  • Mid Cap – Mkt Cap 6500 crores
  • Advice: Investors can BUY with a 2 year perspective

Summary

  • Engineers India is a PSU Mini Ratna engaged in providing engineering and technical services and turnkey projects for the Oil & Gas sector since 1965. It has broadened its activities to related areas. With a HQ in Delhi, company has branches offices in India and abroad.
  • EIL’s growth slowed in the last few years, in line with a slowdown in investments in the sector.
  • However we feel that with the end of the subsidy regime in Indian Oil & gas, and the fall in crude oil prices, the sector is in a turnaround situation. Firms are seeing good refining margins, marginal subsidy issues and robust demand. They are gearing up for capacity and technology upgradation.
  • While revenue and profits at EIL have fallen in 3 years, the share price too fell proportionally.
  • EIL has conservatively preserved cash, built additional capabilities and new growth areas and is poised to recover financially as the sector turns around.
  • Overall Opinion: We feel EIL is a value BUY for investors in this FPO.

Here is a note on the Engineers India Ltd (EIL) Follow on Public Offer (FPO).

FPO Offer

  • The FPO floor price is Rs 189 per share; Applicants may apply at this price, or above, or at Cut Off.
  • There is a 5% discount for Retail investors. 20% of the FPO offer is reserved for Retail.
  • Issue date is Feb 29th Jan, 2016 between 9.15 am to 3.30 pm.
  • The govt. has proposed to sell 3.36 cr equity shares (10%) of stake through an offer for sale (OFS). The govt. is selling this to meet its FY16 divestment targets.
  • The OFS could fetch the govt. almost Rs.635 cr, based on the pricing announced today.
  • P/E as on 27th Jan, 2016 closing price is 23.5 times, which appears high.

READ AND DOWNLOAD THE ENTIRE REPORT

Here is a note on the EIL FPO in PDF format.

JAINMATRIX INVESTMENTS_ENGINEERS INDIA FPO_JAN 2016

Right Click the link above to open/ download the PDF document.

Past Report on EIL 

We have also analysed EIL in the past, see our old report from 2014.

Engineers India FPO 2014

JAINMATRIX KNOWLEDGE BASE 

See other useful reports

  1. Precision Camshafts IPO 
  2. JainMatrix Investments presents the Investment Outlook for 2016
  3. Narayana Hrudayalaya IPO – Investors may not be Patient
  4. Track Record – Dec 2015
  5. Dr Lal Pathlabs IPO
  6. Alkem Labs IPO (premium content)
  7. Goods And Services Tax (GST): Integration And Efficiency
  8. Indigo IPO – Flying High, Wide And Handsome
  9. Café Coffee Day IPO – Very Hot Coffee 
  10. Syngene IPO: Good Pharma R&D spinoff from Biocon.
  11. CPSE ETF – Unlocking Value, Slowly
  12. JainMatrix IPO Reports deliver 60.5% returns

Search for companies/ sectors of your interest in Search box in the right panel.

Visit and Like JainMatrix FB or Follow on JainMatrix Twitter for reports

DO YOU FIND THIS SITE USEFUL?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

DISCLAIMER

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. Punit Jain has a small holding in EIL since Feb 2014. Other than this, JM has no known financial interests in EIL or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any equity investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Punit Jain has applied for certification under SEBI (Research Analysts) Regulations, 2014. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com

Precision Camshafts IPO – an Attractive Finish

  • Date 26th Jan 2016
  • Price range: Rs. 180-186 and Period: 27th – 29th Jan 2016
  • Small Cap – Rs 1750 cr. mkt cap
  • Industry – Auto Ancillary
  • Advice: Investors can BUY with a 2 year perspective

Summary 

  • Overview: Precision Camshafts is a small auto ancillary firm that makes camshafts.
  • Revenues, EBITDA and PAT have grown by 22.3%, 44.1% and 45.3% CAGR over 3 years.
  • Key strengths are good camshafts expertise, global customer base and 78% exports revenues.
  • Customers include GM, Ford Motors, Hyundai, Maruti Suzuki, Tata Motors and M&M
  • Current equity market conditions are positive. The small size of IPO should work in its favour.
  • Some of the negatives include excessive promoter compensation and aggressive IPO price range / high valuations that leave little on the table for value investors.
  • Overall Opinion: Investors can subscribe to this IPO for a 2 year perspective.

Here is a note on Precision Camshafts Limited (PCAM).

IPO highlights

  • The IPO is open from 27-29th Jan 2016 with Issue Price band: Rs.180 -186 per share
  • There are 2.2 crore shares of Face Value: Rs. 10 each on offer to raise Rs. 397 – 410 cr.
  • Purchases may be made in minimum lot size of 80 shares and multiples of 80 thereof.
  • This includes a sale by investors and a fresh issue of shares. The Objects of the IPO issue are:
    • Rs 170 cr. (upper end) – earned by promoter/ investors who reduce stake from 82% to 64%.
    • Rs 200 cr. – establishment of a machine shop for ductile iron camshafts at Solapur factory
    • Rest of the funds – will be used for general corporate purposes.
  • The valuations of PCAM are 27-28 times FY15 and 18-19 times projected FY16 financials.

Introduction

  • Precision Camshafts (PCAM) started in 1992, has HQ in Solapur Maharashtra and is an auto ancillary firm engaged in making camshaft for a range of automobiles.
  • PCAM had revenues and profits of Rs 547 cr. and Rs 62 cr. respectively in FY15.
  • PCAM has a global market share in passenger vehicle (PV) camshafts of  8-9% in 2014.
  • Over 10 years, PCAM has supplied 58 million camshafts to customers in USA, Brazil, UK, Germany, Australia, Hungary, Russia, South Korea, Spain, Uzbekistan, China and India.
  • They are a Tier 1 supplier /OEM for customers like GM, Ford Motors, Toyota, Hyundai, Maruti Suzuki, Tata Motors and M&M. PCAM is also a Tier 2 supplier. (OEM – Original Equipment Mfg.)
  • PCAM has 1,624 employees, and the manufacturing units are in Solapur, Mah. and in Huzhou, China (under JV with Shenglong Automotive Power Train Co Ltd).
  • PCAM supplies over 150 varieties of camshafts for PVs, tractors, light commercial vehicles and locomotive engine applications.
  • Leadership is Mr. Yatin Shah (CMD), Dr. Suhasini Shah (Director) and Mr. Ravindra Joshi (Dir.)

Business News and Updates

  • The camshaft is one of the five critical components of the automobile engine along with the cylinder block, crankshaft, cylinder head and connecting rod.
  • PCAM has a total mfg. capacity as on Sept 30, 2015 of 1.34 cr. camshaft castings from the foundries per annum and 0.22 cr. machined camshafts from the machine shops.
  • The current utilization of these capacities is 75.5% for foundries and 55.1% for machine shops, which places PCAM in a comfortable position in terms of immediate capacity.
  • PCAM is taking up a capacity expansion from 1.35 cr. camshafts to 3.0 cr. by 2017. (2014 news)
  • PCAM won awards for ‘Best Overall Exporter’ and ‘Best Manufacturer Exporter’ from D&B India at the ECGC Indian Exporters’ Excellence Awards among medium exporters in Mar ‘15.
  • PCAM has increased exports, Fig 1. In FY15, the exports /domestic revenue were Rs. 403 /111 cr. resp.
Precision Camshaft - Exports growth, JainMatrix Investments

Fig 1 – Precision Camshaft – Exports growth, JainMatrix Investments

  • At Solapur there is a EOU unit that has 4 foundries and 2 machine shops and a domestic unit.
  • From only mfg. of chilled cast iron camshafts, PCAM has expanded its mfg. to produce ductile and assembled camshafts. It also proposes to set up two new machine shops at Solapur, Mah. for ductile iron camshafts and assembled camshafts by FY17-18.
  • They will also enter into mfg of sliding cams and cam modules as per their expansion strategy.

Acquisitions & JVs

  • In 1999, PCAM entered into a technical and financial JV with G. Clancey Ltd, UK,. In 2006, PCAM acquired the JV by acquiring the stake of its partner. The firm is now called Precision Valvetrain Ltd.
  • In 2011, they incorporated a wholly owned subsidiary ‘PCAM (Shanghai) Co. Ltd in China.
  • In 2012, signed a JV with Shenglong Auto. Powertrain China for a camshaft machining facility.
  • In 2013, signed a JV with Shenglong Auto. Powertrain China and ZMM Technology Ltd, to set up a Foundry for manufacturing 40 lakh camshaft castings per annum at Huzhou in China.
  • In 2014, an exclusive agreement was signed with EMAG, a German machining – tooling firm, for transfer of certain know-how and technology for manufacturing of assembled camshafts. Their camshafts use a force free heat shrink technology which has been patented by EMAG.

Indian Auto Ancillaries Industry

  • Indian auto ancillary industry is a growing fast, riding on the success of the automotive sector.
  • Indian auto component industry clocked a turnover of Rs 2.34 lakh cr. ($38.5 billion) in FY15.
  • Auto components may become the 3rd largest globally by 2016 with 5% of global sales.
  • The autocomp sector recorded a CAGR of 7.8% during the period of 2008-14. In FY15, auto component sales grew 11%, compared with 3% in FY13 and FY14, showing a recovery.
  • Manufacturing expertise, low labour costs, availability of skilled labour and high quality consciousness among Indian vendors are the key strengths.
  • India is also developing as a global mfg. hub for two wheelers and small cars, with robust domestic demand and global export opportunities. Many auto MNCs are setting up here.
  • Outlook: Cooling inflation, growth in urban disposable incomes, and lower interest rates would boost car & bike sales. With an economic recovery, demand for CVs will increase.
  • Auto sector sales are likely to bounce back strongly in the next 2 years, because of improved investment cycles, disposable income and consumer sentiments.
  • According to the ICRA Research, the global PV camshaft volume is estimated to be 10 cr. for 2014 with an estimated market value of Rs 7,000 cr. and is expected to grow at 4% to 5% over medium term. The PV production is estimated to grow at a CAGR of 9-10% by fiscal 2020.
  • Camshaft technology trends: There are increasing govt. regulations to reduce vehicle emission and improve fuel economy. So firms are focusing on altering the structure of camshafts to integrate them with cylinder heads. Assembled camshaft is one such tech where the camshaft is integrated with the cylinder head using hydroforming. This reduces the weight by 60%, reduces rotational inertia, lowers noise and vibration; improves fuel economy, engine dynamics and performance.

Financials of PCAM

  • Revenues, EBITDA and PAT of PCAM have grown by 22.3, 44.1 and 45.3% CAGR over 3 years.
  • Additionally the H1 FY16 performance has been good, indicating an upswing this year. See Fig 2. (Note the projected FY16 data is a simple doubling of H1 results.)
PCAM Financials, JainMatrix Investments

Fig 2 – PCAM Financials, JainMatrix Investments

  • The total debt is Rs 217 cr. The D/E ratio is 0.81 which is moderate (as on 30/09/15, pre IPO). Additionally, reserves are Rs 187 cr. which is healthy.
  • The margins have increased in the last 3 years. OPM has increased from 16.2% to 27.7% and profit margins from 6.5% to 11.4% since 2012. Also in H1 FY16 there appears to be an improvement.
Shareholding Pattern, JainMatrix Investments

Fig 3 – Shareholding Pattern, JainMatrix Investments

  • The promoter stake will reduce from current 82% to 64% post IPO. See Fig 3.
  • PCAM operations have had positive Free Cash Flows only in one of the last 4 years. See Fig 4. However we see this positively as this is due to investments in the business.
Cash Flow, JainMatrix Investments

Fig 4 – Cash Flow, JainMatrix Investments

Benchmarking

In a benchmarking exercise, we compare PCAM to some listed peers. See Fig 5.

Benchmarking, JainMatrix Investments

Fig 5 – Benchmarking, JainMatrix Investments

  • PCAM has leadership across the peer group on Margins. It is also #2 for Sales & Profit growth. Also on ROCE, it is among the leaders. These are impressive ratios.
  • On Debt to Equity ratio, PCAM falls in the average for this group. This is OK.
  • The asking valuations appear stretched as at upper end, P/E is 28.3 times FY15 EPS. This is close to MSS valuations – a highly reputed global firm.
  • Thus while PCAM is a small company in this group, it has so far enjoyed good performance ratios.

Key Strengths of the firm and Positives in IPO

  • The firm is issuing fresh shares for this IPO, which will raise equity and premium funds. These will strengthen the balance sheet and can be used for funding the growth plans of PCAM.
  • With an 8-9% global market share in PVs, and less in other auto categories, there appears to be ample room to grow for PCAM for the next 5-7 years, at current growth rates.
  • With 78% of revenues from exports, PCAM will continue to benefit from INR/USD weakening.
  • It has long term relationships and, in some cases, preferred supplier status, with marquee global OEMs in the auto sector, like GM, Ford Motors, Hyundai, Maruti Suzuki and Tata Motors.
  • PCAM have diversified and expanded mfg. capabilities from chilled cast iron camshafts to ductile iron camshafts and assembled camshafts, and also supply of cam modules and sliding cams. The increase in mfg. and supply of value added products will enhance margins.
  • Thus they are building leadership within the camshaft category. See product range Fig 6.
Fig 6 - Camshafts manufactured (Source: RHP), JainMatrix Investments

Fig 6 – Camshafts manufactured (Source: RHP)

  • PCAM performance and growth indicate a business that is linked to global auto sector.
  • Good manufacturing facilities, technology innovation and engineering expertise.
  • The leadership team of PCAM is an experienced and diverse team of professionals.
  • Increasing geographical penetration and expansion of addressable market.
  • Plans are for inorganic growth which may see growth accelerate in future.
  • The PCAM IPO seems to be well timed. There have been a spate of successful IPOs in India in recent months. Some good IPOs have been heavily oversubscribed.

Internal Risks

  • PCAM has to adhere to strict quality requirements and any failure to comply with these can lead to cancellation of existing and future orders.
  • The 3 top executives of PCAM received Rs 32.4 cr. in FY15 through salary, commissions and benefits. (as per RHP). When compared with Net Profits of Rs 62.4 cr. for PCAM, this appears excessive and out of line with industry standards. Additionally, there are annual increments in their contracts. This will certainly be an interesting topic in post IPO AGM meetings.
  • It appears that PCAM’s customer’s contracts do not include committed purchase volumes and timelines. Hence PCAM has to react to customer requests in short time frames, exposing it to delivery challenges and risks. Or may have to keep high inventory, at higher cost.
  • Volatility in the supply and pricing of raw materials can have an adverse effect on business. However the current fall in prices of metals may be beneficial to PCAM.
  • PCAM is exposed to foreign currency exchange rate fluctuations, which may harm their financials. However, the weakening INR/USD indicates an upside risk to revenues.
  • The IPO valuations of a PE of 27-28 times FY15 and 18-19 times projected FY16 appear to be high in the context of a small cap firm.

External Risks

  • As much as 57.3% of PCAM revenues come from just 2 clients, GM and Ford (source: RHP). This poses a client concentration risk on PCAM business.
  • PCAM caters to global markets and business can be affected by poor global economic conditions.
  • Global auto component players have started operations in India which can pose strong competition.
  • In camshafts, the replacement market is small, so PCAM has to concentrate on OEM business.
  • PCAM has restricted its business to camshafts. While today they can grow within this sector, in the next 5-7 years, they may need to look at other components to expand business.
  • PCAM is a micro to small cap company, and so faces related risks like riskier operations (mfg. is in only one location), high dependency on a few senior executives and on a few customers. The firm may need to plan for derisking business even as it grows fast.

Overall Opinion

  • Indian auto ancillary mfg. is a high potential space with ample domestic demand and global opportunities. India has many competitive & comparative advantages in this sector.
  • PCAM appears to be a focused company with a strong niche, mfg. strengths and good potential. The business is export oriented by nature.
  • Current equity market conditions are positive. Being a smaller IPO may also work in its favour.
  • The negatives include excessive promotor compensation. We also feel that the asking valuations are aggressive and leave little on the table for value investors.
  • However putting all this together, we feel that PCAM, like its products, has an Attractive Finish.
  • Investors can go ahead and BUY this PCAM IPO with a 2 year perspective.

READ AND DOWNLOAD THE ENTIRE REPORT

Here is a note on the PCAM IPO in PDF format.

JainMatrix Investments_Precision Camshafts IPO_Jan2016

Click the link above to open/ download the PDF document.

JAINMATRIX KNOWLEDGE BASE 

See other useful reports

  1. JainMatrix Investments presents the Investment Outlook for 2016
  2. Narayana Hrudayalaya IPO – Investors may not be Patient
  3. Track Record – Dec 2015
  4. Dr Lal Pathlabs IPO
  5. Alkem Labs IPO
  6. Goods And Services Tax (GST): Integration And Efficiency
  7. Indigo IPO – Flying High, Wide And Handsome
  8. Café Coffee Day IPO – Very Hot Coffee 
  9. Syngene IPO: Good Pharma R&D spinoff from Biocon.
  10. Navkar Corp IPO – Location Challenges – Avoid
  11. CPSE ETF – Unlocking Value, Slowly
  12. JainMatrix IPO Reports deliver 60.5% returns

Search for companies/ sectors of your interest in Search box in the right panel.

Visit and Like JainMatrix FB or Follow on JainMatrix Twitter for reports

DO YOU FIND THIS SITE USEFUL?

  • Visit the Investment Servicepage to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

Disclaimer

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. JM has no known financial interests in Precision Camshafts Ltd. or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any equity investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Punit Jain has applied for certification under SEBI (Research Analysts) Regulations, 2014. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com

An IPO Update, Jan 2016

Dear Readers,

The IPOs are happening fast and furious, and in this note we recap recent events and try to look ahead too:

Alkem Laboratories IPO

  • Our investment report is available on link  Alkem Labs IPO Note
  • We had recommended a BUY on Alkem
  • The IPO was open from 8-10th Dec 2015 and Issue Price band was Rs.1020-1050 per share
  • The category wise subscription was:

Alkem IPO

  • The issue price was Rs 1050 and the shares got listed on Dec 23, 2015.
  • As of today the share price is trading at Rs 1552.2 and is up by 47.8%.

DR LAL PATHLABS IPO 

  • Our report link is Dr Lal Pathlabs IPO Note 
  • We had recommended a BUY on Dr Lal Pathlabs.
  • IPO was open from 8-10th Dec 2015, and the Issue Price band was Rs.540-550 per share. There was a retail discount of Rs 15/share on this issue.
  • The category wise subscription was:

DrLal IPO

  • The issue price was Rs 550 and the shares got listed on Dec 23, 2015.
  • As of today the share price is trading at Rs 811.8 and is up by 51.75% in absolute terms.

NARAYANA HRUDAYALAYA IPO

  • Our report link is Narayana IPO Note 
  • IPO was open from 17-21st Dec 2015 and the Issue Price band was Rs.245-250 per share.
  • Worried about valuations, we had recommended an Avoid on this offer.
  • The category wise subscription was as follows:

Narayana IPO

  • The issue price is Rs 250 and the shares are expected to be listed on Jan 6th, 2016 (tomorrow).
  • There is a grey market premium for the share of Rs 30. (Source: Economic Times).

Lets see how this listing turns out.

Happy investing,

Punit Jain

Do you find this site useful?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

Narayana Hrudayalaya IPO – Investors may not be Patient

  • Date 17th Dec 2015
  • Price range: Rs. 245-250 and Period: 17-21st Dec 2015
  • MidCap Rs 5100 cr Mkt Cap
  • Industry – Hospital Services
  • Advice: Avoid 

Summary

  • Narayana Hrudayalaya Ltd was founded by eminent cardiac surgeon Dr Devi Prasad Shetty in 2000. It operates a national network of hospitals, clinics and primary care facilities.
  • NHL’s revenue and EBITDA have grown 30% and 23.8% CAGR over the last 4 years. But the firm slipped into losses in FY15 on account of 3-4 acquisitions.
  • NHL delivers high quality and affordable healthcare services by leveraging economies of scale, skilled doctors, process improvements and an efficient business model.
  • However margins are low. In terms of valuations, NHL has an asking PE of over 200 times FY16 (P) which is very expensive. Thus from an investment perspective, NHL is not attractive at current IPO price points. It may however look attractive for development oriented or philanthropic investors.
  • Opinion: Investors can avoid this IPO.

IPO highlights

  • IPO is open from 17-21st Dec 2015 with Issue Price band: Rs. 245-250 per share.
  • Shares offered to public: 2.45 cr roughly of Face Value: Rs.10 per share. Market Lot: 60 shares and in multiples of 60 shares thereof. Shares offered as portion of equity post issue: 12%
  • Amount proposed to be raised: Rs. 613 cr via OFS route (there is no fresh issue of shares).
  • This IPO is a liquidity event. The shareholders exiting partially are:
Exiting Shareholders

Exhibit 1 – NHL IPO – Selling Shareholders 

Introduction to Narayana Hrudayalaya

  • NHL is a Bangalore based operator of a national network of hospitals, clinics and primary care facilities.
  • NHL had revenues, Ebitda and profits of Rs 1371.6 cr., 136.6 cr. and (-10.9) cr. resp. for FY15.
  • NHL has a network of 23 hospitals (multi-specialty or super-specialty healthcare facilities which provide tertiary care), 8 heart centers and 24 primary care facilities including clinics and information centers, across 31 locations in India. Hospitals generated 90.7% of revenue, heart centers 7.3% and all others 2%.
Facilities Network

Fig 2 – NHL’s existing and upcoming hospitals/ heart centers, source RHP

  • In FY15, NHL provided care to 19.7 lakh patients in 56 facilities with 5,442 operational beds
  • NHL’s centers provide medical care in 30 specialties, including cardiology and cardiac surgery, cancer care, neurology and neurosurgery, orthopaedics, nephrology and urology, and gastroenterology.
  • NHL has 11,163 employees, including 344 doctors, 5,587 nurses, 1,996 paramedical staff and 3,236 admin. personnel. They also have 1,750 consulting doctors engaged to their network.
  • Leadership includes Dr Devi Shetty, Chairman & ED and Dr Ashutosh Raghuvanshi, MD-CEO.
  • 3 of their hospitals are accredited by the JCI, USA for meeting international healthcare quality standards for patient care and organization management, and 6 of their hospitals are accredited by the National Accreditation Board for Hospitals and Healthcare Providers, India.
  • NHL won the “Healthcare Excellence Award for Addressing Industry Issues” in 2012 from FICCI
  • NHL won the “Arcelor Mittal Boldness in Business Award” in 2013
  • NHL received the “Outstanding Achievement Award Healthcare – Social Cause” in 2015

NHL Business News and Insights

  • NHL failed to start construction work for a proposed 1,000-bed cardiac hospital. So the state govt. issued a show cause notice to NHL initiated steps to reclaim the 6 acres of land allotted to NHL near Dumuduma (Bhubaneshwar) in Sept 2008.
  • British govt owned development finance institution CDC invested Rs 300 cr in NHL for a minority share. NHL will use the funds to expand affordable treatment in Eastern, Central and Western regions.
  • NHL raised Rs 183.9 cr. from anchor investors before the IPO opened, at the top end of pricing range.
  • The cardiac hospital in Bangalore performs about 30 heart surgeries daily, the highest in the world, at a break-even cost of Rs 1.2 lakhs. This is significantly lower cost than most other hospitals in India.
  • In line with social objectives, most patients are charged more, but the poorest are treated for free.
  • M&A: NHL acquired Westbank Hospital for Rs. 150 cr. in Nov 2014, also Asia Healthcare Development (AHDL), Meridian Medical Research & Hospital (MMRHL), and Jubilant Kalpataru Hospital in 2014.
  • NHL operates its business through a combination of the following models:
    • hospitals – that they own and operate;
    • hospitals/ heart centers – operate and pay revenue share
    • hospitals, standalone clinics and primary care facilities – operate on a lease or license basis; and
    • hospital management services provided to third parties for a fee – Managed Hospitals.
  • Dr Devi Prasad Shetty is a famous heart surgeon, who founded NHL.
  • He came to the conclusion that the health care industry needs more process innovation than product innovation. The industry “does not need a magic pill or the fastest scanner or a new procedure,” but instead requires improvements that lower the cost of medical attention and make it more widely available. Shetty’s premise of economies of scale is not radical; in fact, the doctor describes his way as “the Walmart approach.” What sets him apart, however, is that he has successfully adapted the method to a field as complex and costly as cardiac care. (knowledge@wharton).
  • NHL provides free treatment or subsidized costs to certain categories of patients. This is part of NHL’s social strategy. In some cases, their agreements with partners or state governments may also specify such quotas/ subsidies. NHL then charges higher to other patients in order to recover these costs.

Industry Outlook

  • According to WHO, India’s total expenditure on healthcare was 4% of India’s GDP in 2013. India trails developed (USA, UK) and also developing countries (Brazil, Russia, China and Thailand) on spending to GDP, due to the under penetration and price sensitivity
  • India is the 10th largest economy (GDP of USD 1.9 trillion) with 20% of the people (1.2 billion).
  • The Govt. accounted for 32.2% of healthcare expenditure in India (2013) a small increase in 10 yrs.
  • A key concern India faces is the affordability of healthcare by a vast majority of its population. According to the WHO, while 58% of the total healthcare expenditure in India is borne by consumers directly (without insurance coverage or reimbursements), this proportion rises to 86% in case of private healthcare services. This has however reduced over the last decade.
  • As per CRISIL estimates the size of the Indian healthcare delivery industry is at 3,400 million treatments in volume terms and Rs 3,80,000 cr. in value terms in 2014-15. The healthcare delivery market would grow at a CAGR of 12% till 2020.
  • Cardiac care has the highest average realization per patient (CRISIL).
Exhibit 3 – Average realization for various ailments, Source RHP, JainMatrix Investments

Exhibit 3 – Average realization for various ailments, Source RHP

  • A key cost factor in a hospital is the initial capital outlay required, particularly for land, building development and equipment. The capital cost to build a hospital is typically Rs 70-80 lakhs per bed (for a typical 200 bed multispecialty hospital, excluding land costs).
  • The drivers of growth in the healthcare delivery market in India are:
    • Potential in bed capacity – India’s bed density is 7/10,000 people (global median – 27 beds).
    • Govt spending on healthcare will remain low, allowing private sector to increase presence
    • Increasing population as well as life expectancy to require greater health coverage
    • Rising income levels to make quality healthcare services more affordable
    • Growth in medical tourism, cosmetic medical services to aid demand growth
  • Anecdotal evidence points to falling medical standards in large hospitals:
    • Cesarean births are rising alarmingly as a ratio to natural deliveries in many regions.
    • Many large urban hospitals target affluent patients with a battery of unnecessary tests and procedures, effectively milking the patient under the guise of a doctor’s line of treatment.
    • Medical services are only as good as the person serving you. Stories abound of medical negligence like silly errors during operations, nurses and staff missing pre or post operation, etc.
    • Inflated medical bills for patients with insurance
  • There appears to be a shortage of medical nursing staff. This is attributed to a lack of professional growth in India (and ample opportunities abroad). Nurses in India are not allowed to carry out simple medical tasks, which are reserved for doctors, thus limiting their professional growth.
  • Medical Colleges and higher education are constrained by limited seats and high costs.
  • Many such issues fall under the purview of the Medical Council of India.

Financials of NHL

  • The EPS of NHL has grown 32.5% CAGR from the year 2011-2014 which is a positive sign of high growth potential. However in FY15 NHL posted a loss of Rs 10.9 cr. Also again it has turned PAT positive for HI FY16. Note FY16P data is a simple doubling of H1 data.
  • NHL’s revenue and EBITDA has grown 30% and 23.8% CAGR over the last 4 years. This is excellent.
  • Margins have become thinner for NHL in the last 4 years. See Fig 4.
Fig 4 – NHL Financials, JainMatrix Investments

Fig 4 – NHL Financials, JainMatrix Investments

  • NHL has been operating cash positive over 5 years, but the free cash flows are negative. Fig 5.
Fig 5 – NHL cash flow, JainMatrix Investments

Fig 5 – NHL Cash Flow

Positives for the IPO

  • NHL has a social commitment to provide subsidized/free services to some patients.
  • Dr Devi Shetty has through NHL created a ‘Walmart’ type business model for high end services like heart surgeries, and has lowered costs while delivering high quality. This is widely recognized in the industry and NHL/ Dr Shetty have been awarded many times for these achievements.
  • NHL has a strong brand ‘Narayana Health’ with good presence in Karnataka & East India. Its has a reputation for clinical excellence and affordable healthcare.
  • NHL is setting up in the NorthEast and Vaishno Devi (where hospital facilities are scarce), Lucknow (multi-specialty hospital), Mumbai (pediatric hospital) and Bhubaneshwar (tertiary care).
  • NHL is strong in many segments, but particularly in cardiology and cardiac surgery.
  • Capital efficiency – NHL’s capital cost is Rs 25.5 lakhs/bed in FY2015 (industry avg 70-80 lakhs/ bed).
  • Ability to attract high quality doctors and medical support staff.
  • Experienced management team with a strong execution track record.
  • Anecdotal evidence suggests that the NHL chain appears to have a better reputation in terms of patient care, good medical advice and trustworthy services than other large hospital chains.

Internal Risks 

  • Dr Devi Shetty has built NHL to this scale, but there may be a need to broad base the firm’s leadership so that it can become an institution, rather than be dependent on a few leaders.
  • Just three large hospitals contribute 58% of total revenues currently. Thus any disruption to any of these 3 will affect their business.
  • A majority of NHL doctors are not employees but medical consultants. There is no assurance that they would continue to provide services to NHL on an ongoing basis. This can affect business.
  • NHL has in the past ceased operations and decommissioned beds at some facilities. NHL may not be able to successfully implement all their growth strategies, particularly in Tier II and Tier III cities.
  • Litigation related to medical services, from patients is a business risk.
  • They recently acquired a third party hospital and two hospitals companies. These and any future acquisitions may present integration challenges or turn out to be unprofitable. Acquisitions carry the inherent risk of past non-compliance and undisclosed liabilities.
  • NHL is exposed to business risks related to clinical trials undertaken and stem cells they preserve.
  • The IPO is a liquidity event and an exit platform. Funds raised will not benefit NHL.

External Risks

  • In general, a number of govt. and regulatory registrations, licenses and approvals have to be obtained. In particular, Narayana Hospitals and AHDL have not obtained occupancy rights over certain hospitals and clinics they operate out of, and not obtained ownership rights over certain lands forming part of NH Health City and certain superstructures constructed by them in RTIICS. They run the risk of being dispossessed of these properties. (RHP)
  • The Central or State Governments may exercise rights of eminent domain in respect of the land on which NHL’s facilities are situated.

Benchmarking

In a benchmarking exercise, we compare NHL with some listed peers.

Exhibit 6 - Benchmarking, JainMatrix Investments

Exhibit 6 – Benchmarking, JainMatrix Investments

  • Sales at NHL have shown an impressive growth.
  • But valuations look expensive. Since there was a loss in FY15, the PE is not mentioned. But estimated PE for FY16 falls in the 200-205 range, a very high number.
  • Even on EV/EBITDA and EV/ Sales, NHL falls at the higher end among its peers.
  • Debt levels are reasonable, not high. But return ratios are quite low.
  • The reason we can find for low margins and even losses in FY15 are – several acquisitions were made in this year, which are integral with NHL’s growth strategy. However these operations are yet to contribute to the returns for NHL.

Overall Opinion

  • India with its large and growing population is badly stretched in terms of quality healthcare facilities. Expenditure in this sector will trend upwards. Govt’s (free) facilities cater to the low end of market.
  • NHL has a good brand name and sustainable model for providing quality and affordable healthcare. It has lowered the costs of delivering complex procedures, while also meeting social objectives.
  • The pricing for NHL IPO looks stretched from various angles. In FY 2015, NHL suffered a loss. At the projected FY16 profits, the PE looks like 200-205 times.
    • Perhaps NHL has in an attempt to grow fast and acquire companies, compromised on profits for FY2015 and FY2016. Modern companies are making such trade-offs.
    • Perhaps NHL has sacrificed profits for its social objectives. It can easily improve margins but takes on a number of free or subsidized procedures and ‘does good rather than just make money’.
    • Can the trustworthiness and technical competence at NHL justify a big pricing premium to the peers in Exhibit 6?
  • NHL does not have positive free cash flows since 5 years.
  • NHL executives need to clearly articulate their profit or social objectives to potential investors and shareholders, especially since these clash with each other.
  • We conclude from this that for investors, NHL is not attractive at current price points. But it may look attractive for development oriented or philanthropic investors.
  • Investors should avoid this IPO and look to enter the counter at lower levels.

READ AND DOWNLOAD THE ENTIRE REPORT

Here is a note on the NHL IPO in PDF format.

JainMatrix Investments_Narayana Hrudalaya IPO_Dec 2015

Click the link above to open/ download the PDF document.

JAINMATRIX KNOWLEDGE BASE 

See other useful reports

  1. Track Record – Dec 2015
  2. Dr Lal Pathlabs IPO
  3. Alkem Labs IPO
  4. Goods And Services Tax (GST): Integration And Efficiency
  5. Indigo IPO – Flying High, Wide And Handsome
  6. Café Coffee Day IPO – Very Hot Coffee 
  7. Syngene IPO: Good Pharma R&D spinoff from Biocon.
  8. Navkar Corp IPO – Location Challenges – Avoid
  9. CPSE ETF – Unlocking Value, Slowly
  10. JainMatrix IPO Reports deliver 60.5% returns

Search for companies/ sectors of your interest in Search box in the right panel.

Visit and Like JainMatrix FB or Follow on JainMatrix Twitter for reports

Do you find this site useful?

  • Visit the Investment Servicepage to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

Disclaimer

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. JM has no known financial interests in Narayana Hrudalayala Ltd. or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com

Dr Lal Pathlabs IPO – Essential Services are an Essential Buy

  • Date 9th Dec 2015
  • Price range: Rs. 540-550 and application period: 8-10th Dec
  • Industry: Pharma – Diagnostic services
  • Mid Cap – Rs 4550 cr Mkt Cap 
  • Advice: Retail Investors can BUY with a 2-3 year perspective

Summary

  • Overview: DLP is provider of diagnostic and related healthcare tests and services.
  • DLP’s Revenue, EBITDA and EPS have grown at 29.2%, 29% and 33.9% CAGR over 4 years.
  • Key strengths are a proven, robust ‘hub and spoke’ model which allows consistent service levels and rapid growth. It is the #2 player in this space, with a strong North India presence. It has a good brand in this niche, which can be leveraged. DLP’s model is scalable; its reach can be expanded rapidly. Also it’s not a discretionary service, more like an essential service.
  • In terms of valuations, DLP has an asking PE of 54.5 times FY16 (P) which looks expensive. However we feel that the business can be valued closer to retail food services than hospitals.
  • As an investment, the DLP IPO is rated a medium risk, high return type of offering.
  • Opinion: Investors can subscribe to this IPO for a 2-3 year perspective.

Here is the investment note on Dr Lal Pathlabs (DLP).

IPO highlights

  • IPO is open from 8-10th Dec 2015 with Issue Price band: Rs.540-550 per share
  • Shares offered are 1.16 cr. of FV: Rs. 10 per share, and amount to be raised: Rs.638 cr. via OFS route. Shares offered as portion of equity post issue: 14.1%.
  • Market Lot: 20 shares and in multiples of 20 shares thereof.
  • There is a Rs 15 discount for Retail.
  • Objects of the issue: Promoters, promoter group and investors are exiting partially from their investments. No funds raised in IPO will benefit the company directly.
  • The promoter stake will reduce from 63.7% to 58.7% post IPO. Also the Pre IPO shareholding of the private investors/ VCs was 32.2% which would get reduced to 23.2% once the shares get listed.

Introduction

  • DLP is a Delhi based provider of diagnostic and related healthcare tests and services.
  • DLP had revenues, EBITDA and profits of Rs 662 cr, Rs 158.9 cr and Rs 95 cr. in FY15.
  • DLP’s network includes National Reference Lab in New Delhi, 171 clinical labs, 1,554 patient service centers and 7,000 pickup points. Network is all India, but unevenly spread, see Fig 1-2.
  • Customers include individual patients, hospitals, other healthcare providers and corporates.
  • DLP is staffed with 3,253 full-time employees and 83 full-time consultants (contractual).
  • DLP has built a national, “hub and spoke” network. Specimens are collected across multiple locations in a region for delivery to a designated clinical laboratory for centralized diagnostic It provides them with greater economies of scale and is the platform for good growth.
  • DLP provides has over 3,495 diagnostic and related healthcare tests and services including – Routine clinical lab tests (blood chemistry analyses and blood cell count), Specialized testing (histopathology, genetic marker, viral and bacterial cultures and infectious disease); and Preventive testing services (screenings for hypertension, heart disease and diabetes).
  • DLP was started by late Dr. Major S.K. Lal in 1949, by providing pathology services and maintaining a blood bank. The current leadership is Brig. Dr. Arvind Lal (CMD), Dr. Vandana Lal (Dir.), Dr. Om Prakash Manchanda (Dir & CEO) and Mr. Dilip Bidani (CFO).
  • The Pre IPO shareholding of private investor/ shareholders was 32.2% which would get reduced to 23.2% post IPO. Private equity/ VC investors like Wagner Ltd., WestBridge Crossover Fund, LLC and Sanjeevini Investment Holdings are associated with DLP.
  • The key strategy of DLP is to continue to expand their presence in the markets in which they operate and also into other markets in India through strategic acquisitions and partnerships.
  • For FY15, 72% of the revenues were from the Northern region. Currently the focus of the company is to strengthen and expand their presence in Central and Eastern India. A new large, regional reference laboratory is under construction in Kolkata.
Fig 1 - Revenue Segments, JainMatrix Investments

Fig 1 – Revenue Segments, JainMatrix Investments

Fig 2 – Service Network, Source DRHP

Business News and Updates

  • DLP had announced its plan to expand operations in Bengaluru through new centers and labs to reach a total number of 50 centers (from current 20) by Dec 2015.
  • BD India and DLP inaugurated a Centre of Excellence in Phlebotomy (blood collection, sampling) in June 2015. This center was launched to provide certified phlebotomy courses to healthcare professionals, and improving best practices for accurate and reliable diagnosis.
  • DLP had acquired Ashish Pathology Labs, a lab in Ahmedabad as part of its acquisition strategy to expand inorganically last year. It has been growing mainly through organic expansion. In northern, eastern and central India it has been adding 20-25 labs year on year.
  • As per DLP, “each lab costs around Rs 1 crore and there are additional investments in facilities like IT among others. Overall, we invest Rs 40-50 crore for our expansion every year”.
  • DLP has sample collection centers in 9 countries and plans to start in Africa with Nigeria.
  • Per latest data, DLP on day 2 of IPO is 2.65 times subscribed a sign of good success.

Industry Outlook

  • According to the World Health Organization (WHO), India’s total expenditure on healthcare was 4% of the GDP as of 2013. India trails both developed countries (USA, UK) and also developing countries (Brazil, Russia, China and Thailand) in healthcare spending % of GDP. This is due to the under penetration of healthcare services as well as partial govt. ownership.
  • As per CRISIL Research, the Indian diagnostics industry is at Rs 37,700 cr. in FY15. It will continue to grow by 16-17% CAGR over the next three years to over 60,000 cr. by FY18.
  • Demand drivers for the Indian diagnostic industry include:
    • Increase in evidence-based treatments; Changing disease profiles; big demand-supply gap;
    • Increase in health insurance coverage; Need for greater health coverage as population and life expectancy increase; Rising income levels make quality healthcare services affordable
    • Growing demand for lifestyle diseases-related healthcare services
  • Urban areas account for a higher proportion of revenues in diagnostics industry, as the urban population (28% of population) contributes 67% of revenues (CRISIL Research).
  • DLP trails only Fortis Healthcare controlled SRL in the diagnostics business. SRL had acquired Piramal Diagnostics to become the top player in the industry four years ago.
  • The Govt. accounted for 32.2% of healthcare spends in India (2013), a small increase in 10 yrs.

Financials of DLP

  • DLP’s Revenue, EBITDA and EPS have grown at 29.2%, 29% and 33.9% CAGR over 4 years.
  • This is excellent as it indicates that the business is in high growth mode. Even with increasing competition and declining margins, the performance looks good. See Fig 3.
Fig 3 - Pathlabs Financials, JainMatrix Investments

Fig 3 – Pathlabs Financials, JainMatrix Investments

  • However H1FY16 results were disappointing and the projected EPS for FY16 is Rs 10.1, whereas it was Rs 11.5 for FY15. This is a negative sign. Note FY16P data is a simple doubling of H1 data, also accounting for one time/ exceptional charges related to IPO.
  • Currently DLP has zero outstanding borrowings as well as term loans. This is a big plus from the financial perspective. DLP has the option to raise funds in future if required.
  • The operating margins have declined to 24% from 25.5% in 2012. However the profit margins have improved from 12.4% in 2011 to 14.3%. But Profit margins fell in H1FY16 to 9.2%.
  • DLP’s operations have been both operating and free cash flow positive since 5 years. This is positive. But there is a declining trend due to increasing investments in the business. Fig 4.
Fig 4 - Cash Flow, JainMatrix Investments

Fig 4 – Cash Flow, JainMatrix Investments

Positives for Dr Lal Pathlabs and IPO:

  • DLP financials have shown strong growth in 4 years. DLP has been acquiring small medical labs to grow inorganically. Such growth is also sustainable.
  • DLP has a strong footprint in the North. Expansion in South & East will give a further impetus.
  • They have built a good brand in diagnostics which is likely to strengthen in the near future.
  • DLP uses a ‘Hub and Spoke’ business model, which allows consistent service levels and rapid growth.
  • Experienced leadership team includes professionals with strong industry expertise and track record.

Internal Risks

  • The Dr Lal PathLabs brand is fundamental to their business, and any failure to maintain the quality of their diagnostic healthcare services provided could affect their business.
  • Business interruptions at DLP’s National Reference Laboratory may also affect operations.
  • DLP’s business depends on franchisees and business partners. Any non-performance by them may adversely affect DLP. Some of their lab operations are undertaken jointly with third parties, whose interests may differ from DLP’s, and such arrangements entail certain risks.
  • DLP leases the majority of its laboratories and other business premises. They might not be able to renew any such leases on favorable terms, and costs will rise.
  • DLP is subject to seasonal fluctuations in operating results and cash flows. Diagnostic healthcare testing volumes typically increase during the monsoon season and experiences slower business during Dec-Jan, when the temperature and humidity are lower.
  • For DLP, the employee benefit expenses have risen sharply over the last 5 year reflecting shortages in medical / doctor staff. If this accelerates, it can impact profitability.

External Risks

  • DLP operates in a competitive business environment which has low barriers to entry.
  • Diagnostics business is still dominated by unorganized local centers rather than large chains.
  • The business is subject to a variety of central and state govt taxes and surcharges, and any increase in tax rates — such as GST, could adversely affect their financials.
  • Political instability or disruptions at locations where they operate can affect business.

Benchmarking

Exhibit 5 - Benchmarking, JainMatrix Investments

Exhibit 5 – Benchmarking, JainMatrix Investments

We compare DLP with hospital chains as well as retail focused service companies:

  • DLP emerges quite strongly across parameters like margins, growth, and return ratios.
  • It does not lead the pack on the valuation parameters.
  • Based on this it appears that the valuations of DLP may fall somewhere between established hospital chains and the leading retail service business.

Overall Opinion

  • India with its large and growing population is stretched in terms of available healthcare facilities. Expenditure in this sector will trend upwards. Govt’s (free) facilities cater to the low end of market.
  • In this space, DLP’s diagnostic and healthcare services provide an essential, high demand service. Its not a discretionary service, more like an essential service.
  • The business model is robust and scalable, and there are clear benefits of a national chain over small and local service providers.
  • DLP has a good brand and solid service delivery in the North, where it is established. We believe that DLP will be able to grow and roll out a national (urban) footprint. The next target would be semi urban and rural areas. There is massive potential to grow over the next 10 years.
  • In terms of valuations, DLP has an asking PE of 54.5 times FY16 (P) which looks expensive. However we feel that the business can be valued closer to a retail food service than a hospital. DLP’s model is scalable; its reach can be expanded rapidly.
  • As an investment, the DLP IPO is rated a medium risk, high return type of offering.
  • Retail Investors can BUY this IPO with a 2-3 year perspective.

READ AND DOWNLOAD THE ENTIRE REPORT

Here is a note on the Dr Lal Pathlabs IPO in PDF format.

JainMatrix Investments_Dr Lal PathLabs IPO_Dec 2015

Click the link above to open/ download the PDF document.

JAINMATRIX KNOWLEDGE BASE 

See other useful reports

  1. Alkem Labs IPO
  2. Goods And Services Tax (GST): Integration And Efficiency
  3. Indigo IPO – Flying High, Wide And Handsome
  4. Café Coffee Day IPO – Very Hot Coffee 
  5. Syngene IPO: Good Pharma R&D spinoff from Biocon.
  6. Navkar Corp IPO – Location Challenges – Avoid
  7. CPSE ETF – Unlocking Value, Slowly
  8. JainMatrix IPO Reports deliver 60.5% returns

Search for companies/ sectors of your interest in Search box in the right panel.

Visit and Like JainMatrix FB or Follow on JainMatrix Twitter for reports

Do you find this site useful?

  • Visit the Investment Servicepage to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

Disclaimer

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. JM has no known financial interests in Dr Lal Pathlabs Ltd. or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com

Alkem Labs IPO

Dear Reader,

The IPO season in India continues with another bunch of offerings planned in December 2015.
We have created a new IPO report on Alkem Labs.
It is the first large pharma company IPO in over 10 years.
Its got a lot going for it. At the same time, the criticism can be on the grounds of high valuations, litigation, low exports proportions, etc.

We’ve had good success with our IPO reports, and at one time provided readers 60.5% returns within one year on our recommended IPOs.

Starting this IPO, we will restrict some of our IPO reports to our Subscribers for the Investments Service. However we share with you the IPO highlights:

IPO highlights

alkem labs, jainmatrix investments

  • IPO is open from 8-10th Dec 2015 with Issue Price band: Rs.1020 -1050 per share
  • Shares offered in IPO are 1.29 crores of Face Value: Rs.2 per share
  • Minimum lot size: 14 shares and multiples of 14 thereof.
  • Shares offered as portion of equity post issue: 10.75% approx.
  • Amount proposed to be raised: Rs.1350 crores via OFS route.
  • There is no fresh issue. The promoter stake would reduce from the existing 70.9% to 66.2% post IPO.
  • Objects of the issue: Promoters, promoter group and investors are exiting partially from their investments. No funds raised in IPO will benefit the company directly.

Good luck and happy investing,

Punit Jain

JAINMATRIX KNOWLEDGE BASE:

  1. A View on the Indian Rupee
  2. Goods and Services Tax (GST): Integration and Efficiency
  3. Power Sector – A Complex Challenge
  4. The Roads Sector – Is it a Revival?
  5. The Slide of Oil – Positive for the Economy
  6. A PSU firm with a projected 80% gain in 2 years (premium content)
  7. Indigo IPO – Flying High, Wide And Handsome
  8. Cafe Coffee Day IPO – Very Hot Coffee
  9. Auto Ancilliary Small Cap (premium content)
  10. CPSE ETF – Unlocking Value, Slowly
  11. IPO Reports deliver 60.5% returns
  12. Large Cap and Mid & Small Cap Portfolio reports (premium content)
  13. Seven Short Steps to Long Term Investing Success

DO YOU FIND THIS SITE USEFUL?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

Disclaimer

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. JM has no known financial interests in Alkem Laboratories or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Punit Jain has applied for certification under SEBI (Research Analysts) Regulations, 2014. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com

IPO Updates, CCD and IndiGo

Dear Investor,

Find here our IPO report updates:

Café Coffee Day IPO UPDATE 

Here is a short listing day report on the Coffee Day IPO.

  • On 10th Oct, we had rated the IPO as an Average offering. See entire report:
  • Café Coffee Day IPO – Very Hot Coffee 
  • The IPO received lukewarm response with a 1.8 times subscription. This is low by our general IPO standards. It garnered over Rs 2000 cr. on an offering of Rs 1150 cr.
  • Categories of Retail, QIB and non-institutional NII received 0.9, 4.4 and 0.53 times subscription
  • The IPO listing price was however declared at the upper end of Rs 328.
  • The share has listed today and so far we are seeing a weak performance, with a 16% fall below this price to the current Rs 275. (at 1.30 pm)

CCD Offering Overview:

  • Price range: 316 – Rs. 328 Per Equity Share and IPO Period:  Oct 14–16, 2015
  • Mid Cap – Rs 4,979 cr Mkt Cap
  • Industry – Coffee QSR, conglomerate
  • Advice: Average offering with medium to high risks.

 IndiGo IPO UPDATE 

Here is a short post IPO offering report on the Coffee Day IPO.

  • On 27th Oct, we had rated the IndiGo IPO as a Good offering. See entire report:
  • Indigo IPO – Flying High, Wide And Handsome
  • The IPO received a healthy response with a 6.15 times subscription. Given the size of Rs 3,018 of the offering, this means applications were for a massive Rs 19,000+ crores.
  • Retail, QIB and NII category got subscribed 0.92, 17.8 and 3.57 times respectively.
  • Listing is expected around Nov 13th (As per the rules pertaining to the IPO market, the shares of any company should be listed on stock exchanges for trading by 12th working day from the IPO issue close date.)

IndiGo Offering Overview:

  • IPO Period: 27-29th Oct 2015 and Price range: Rs. 700-765
  • Industry – Airlines
  • Large Cap – 27,600 cr mkt cap
  • Advice: Good offering with medium risks. BUY with a minimum 1 year horizon.

Disclaimer

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. JM has no known financial interests in IndiGo or Interglobe Aviation or CCD or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Punit Jain has applied for certification under SEBI (Research Analysts) Regulations, 2014. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com